The global assisted reproductive technology market share in 2026 is witnessing significant growth as infertility becomes increasingly prevalent across different regions and demand for fertility treatment continues to rise. According to Fortune Business Insights, the global assisted reproductive technology market size was valued at USD 42.37 billion in 2025. The market is projected to grow from USD 46.14 billion in 2026 to USD 91.33 billion by 2034, exhibiting a CAGR of 8.91% during the forecast period. Europe dominated the assisted reproductive technology market with a share of 41.18% in 2025.
Assisted reproductive technologies, also known as assisted reproductive treatment, include medical techniques used to treat infertility. These procedures cover a broad range of fertility treatments depending on the underlying causes of infertility. Key techniques include in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo transfer (FET), and other assisted reproductive procedures.
Assisted reproductive technologies involve procedures in which eggs and embryos are handled and are different from therapies that rely only on medication. Increasing awareness regarding fertility services, technological advancements, and the availability of specialized treatment options are supporting the adoption of these procedures across healthcare settings.
The rising prevalence of infertility worldwide is a major factor supporting the growth of the assisted reproductive technology market. Changing lifestyles, increasing stress levels, obesity, and other factors are contributing to the growing prevalence of infertility among both male and female populations. Increasing infertility rates in countries such as China, the U.S., the U.K., and India are expected to create continued demand for ART procedures.
Government initiatives and support from non-profit organizations are also helping improve access to fertility treatments. These initiatives are aimed at making fertility services more affordable for the general population in developed and emerging countries. In addition, advancements in assisted reproductive technologies, including intracytoplasmic sperm injection, intrauterine insemination, and frozen embryo transfer, are supporting market expansion.
However, high treatment costs remain a major restraint. The expense associated with fertility procedures can limit access, particularly in emerging countries. Socio-ethical stigma surrounding assisted reproductive procedures also continues to restrict adoption in certain populations.
The competitive landscape consists of companies and fertility service providers focusing on expanding their service portfolios, strengthening operating networks, and providing technologically advanced and cost-efficient ART services. Bloom IVF Centre, European Sperm Bank, and California Cryobank are identified among the leading providers of fertility services globally.
Market participants are emphasizing specialized fertility services and broader access to reproductive technologies. Strategic developments and acquisitions are also contributing to competitive activity. For instance, Silverfleet Capital Partners acquired a major stake in CARE Fertility in April 2019 to diversify its product portfolio and strengthen its market position. In July 2019, Monash IVF Group acquired Fertility Solutions, a Queensland-based fertility services provider, to increase its global presence.